Anita Treohan
Corporate Officer/Principal en AVROBIO, INC. .
Perfil
Anita Treohan is currently working as the VP-Clinical Development Operations at Avrobio, Inc. Previously, she worked as the Director-Clinical Operations at ImmusanT, Inc. She completed her graduate degree at Boston University and her undergraduate degree at Emory University.
Cargos activos de Anita Treohan
| Empresas | Cargo | Inicio |
|---|---|---|
| AVROBIO, INC. | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Anita Treohan.
| Empresas | Cargo | Fin |
|---|---|---|
ImmusanT, Inc.
 ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formación de Anita Treohan.
| Boston University | Graduate Degree |
| Emory University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| AVROBIO, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
ImmusanT, Inc.
ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Anita Treohan
